Navigation Links
Amgen and Wyeth Statement on FDA Announcement About Tumor Necrosis Factor (TNF) Blockers
Date:8/4/2009

THOUSAND OAKS, Calif. and COLLEGEVILLE, Pa., Aug. 4 /PRNewswire-FirstCall/ -- Amgen (Nasdaq: AMGN) and Wyeth Pharmaceuticals, a division of Wyeth (NYSE: WYE), issued a statement in response to the Food and Drug Administration (FDA) announcement regarding the results of a safety review of Tumor Necrosis Factor (TNF) blockers [marketed as Remicade(R) (infliximab), Enbrel(R) (etanercept), Humira(R) (adalimumab), Cimzia(R) (certolizumab pegol) and Simponi(R) (golimumab)]. This safety review was the subject of an FDA Early Communication in June 2008 pertaining to cases of malignancy in pediatric patients exposed to a TNF blocker. As a result of this review, the FDA has required strengthened warnings about the occurrence of lymphoma and other cancers in children and young adults using these medicines.

AMGEN AND WYETH STATEMENT:

Amgen and Wyeth believe that ENBREL continues to offer a favorable benefit-risk relationship for patients with the diseases for which it is indicated to treat, including moderate to severe Juvenile Idiopathic Arthritis (JIA). JIA can be a serious and potentially debilitating condition. Amgen will work with the FDA to update the U.S. Prescribing Information, and Medication Guide for ENBREL as described in the FDA communication which can be read at http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm175803.htm. In addition, Amgen and Wyeth will communicate the revised product labeling to both physicians and patients.

ENBREL was first approved for JIA in the U.S. in 19
'/>"/>

SOURCE Amgen
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11

Related medicine news :

1. Major Pharma Clinical Case Studies From Amgen, AstraZeneca, GSK, Intermune, Cephalon Inc, Sunesis Pharmaceuticals and Dartmouth Medical School During Fall Clinical Focused Programs
2. InteKrin Therapeutics, Inc. Appoints Former Amgen Clinical Development Executive Chief Medical Officer
3. OmniPod(R) Insulin Management System Lets Team Type 1 Members Focus on Competing at Amgen Tour of California
4. Amgen to Present at the Barclays Capital Global Healthcare Conference
5. Amgen Announces Webcast of 2009 First Quarter Financial Results
6. Amgens First Quarter 2009 Adjusted Earnings Per Share Decreased 4 Percent to $1.08
7. Amgen and ONSEdge Partner With Cancer Survivor Jan Ping for New Campaign
8. Amgen to Present at the Deutsche Bank 34th Annual Healthcare Conference
9. Amgen Highlights Data to Be Presented at ASCO
10. Amgens Denosumab and Eli Lillys Forteo/Forsteo Will Drive Robust Annual Growth in the Osteoporosis Drug Market From 2013 to 2018
11. Loyola fellow receives Amgen grant to study treatments for older leukemia patients
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/29/2015)... Los Angeles, CA (PRWEB) May 29, 2015 ... giant leap forward in Los Angeles thanks to the ... Mohebi. Dr. Mohebi has combined ARTAS hair ... the most advanced hair restoration procedures available anywhere. , ... process of directly and individually harvesting hair follicle grafts ...
(Date:5/29/2015)... CO (PRWEB) May 29, 2015 ... new addiction, substance abuse, and co-occurring mental health ... and ribbon cutting for the general public on ... 2nd. , The Recovery Village at Palmer Lake ... intensive outpatient programming, utilizing traditional and evidence-based therapies, ...
(Date:5/29/2015)... Red Hot & Blue Restaurants , ... & Blue restaurant at 525 New Waverly Place in Cary, ... “The Red Hot & Blue Restaurant was previously located in ... have moved to a new location in the center,” said ... all the activities on the Promenade–with outdoor seating and service, ...
(Date:5/29/2015)... San Diego, California (PRWEB) May 29, 2015 ... Common Core” and have joined the national effort to teach ... Many parents in the U.S. have been “sickened” by the ... country. However, love it or hate it, Common Core is ... the District of Columbia. Parents are now seeking ways ...
(Date:5/29/2015)... Mediaplanet has joined forces with Raw Elements ... importance of proper sun protection. The print component of ... circulation of approximately 250,000 copies and an estimated readership ... through a vast social media strategy, and across a ... explore the digital version of the campaign, click ...
Breaking Medicine News(10 mins):Health News:Los Angeles and Beverly Hills Hair Transplant Doctor Now Combines Robotic Hair Restoration (ARTAS) and Manual FUE Transplants for Maximum Hair Coverage 2Health News:Advanced Recovery Systems Announces the Opening of The Recovery Village at Palmer Lake 2Health News:Red Hot & Blue Restaurant Opens in Cary, North Carolina 2Health News:Red Hot & Blue Restaurant Opens in Cary, North Carolina 3Health News:Red Hot & Blue Restaurant Opens in Cary, North Carolina 4Health News:Doctors Discover a Cure for the Common Core 2
... ... the award-winning educational television program, “Insights” with Hugh Downs, as part of an upcoming ... ... Emerald Express International , a visionary company dedicated to bringing the highest-quality consumable ...
... ... 10-minute, Non-radioactive 13C-urea Breath Testing to the Western U.S. States. , ... Newfields, NH (PRWEB) ... diagnosis and monitoring of gastroenterological and liver related diseases, today announced it has ...
... ... of people between the ages of 35 to 44 have lost a tooth, ... the age of 74. With permanent tooth replacement treatments such as dental implants ... unique incentive for patients who don’t want the hassle of long waiting periods ...
... ... Initiated Studies Offers Expanded Features for Compliance and Effectiveness. , ... Charlottesville, VA, San Francisco, CA, New York, ... openQ has released an expanded offering for managing Investigator Initiated Studies/ Trials (IIS/IIT). ...
... ... Pioneer , ... May 26, 2010 -- Optovue, the company that launched the first FDA cleared Fourier/spectral ... over the same period in fiscal 2009., , ,“Following our 19% revenue growth in 2009 ...
... ... utilizes social media to spread the word. , ... Newcastle, Maine (Vocus) May 26, 2010 -- A new effort to gather ... Social Security Stories Project is seeking story submissions from the public, with a goal ...
Cached Medicine News:Health News:Emerald Express International to be Featured on ‘Insights' with Hugh Downs this Spring in a Segment that Spotlights Glutathione and Anti-Aging 2Health News:Emerald Express International to be Featured on ‘Insights' with Hugh Downs this Spring in a Segment that Spotlights Glutathione and Anti-Aging 3Health News:Exalenz Bioscience Expands Market Coverage for the BreathID Breath Test System 2Health News:Exalenz Bioscience Expands Market Coverage for the BreathID Breath Test System 3Health News:As Popularity of Dental Implants Rise, a Chicago Cosmetic Dentistry Practice's On-site Lab Offers Patients a Unique Incentive 2Health News:As Popularity of Dental Implants Rise, a Chicago Cosmetic Dentistry Practice's On-site Lab Offers Patients a Unique Incentive 3Health News:OpenQ Announces the Release of openIIS 2.5 2Health News:Optovue Q1 2010 Revenue Up 57% Over Same Quarter 2009 2Health News:New Project Gathers Stories about Social Security for Book, Awareness Effort 2Health News:New Project Gathers Stories about Social Security for Book, Awareness Effort 3
(Date:5/29/2015)... , May 29, 2015 /CNW/ - Covalon Technologies ... advanced medical technologies company, is delighted to announce ... March 31, 2015, which includes revenue for three ... quarter of $264,340. Revenue from advanced wound care product ... 31, 2015 increased 24% to $1,742,672 compared to ...
(Date:5/29/2015)... VANCOUVER, British Columbia and ... DelMar Pharmaceuticals, Inc. (OTCQX: ... focused on developing and commercializing proven cancer therapies ... data at the American Association of Cancer ... on the potential for its lead product ...
(Date:5/29/2015)... May 29, 2015  Eli Lilly and Company (NYSE: ... today announced that they have entered into a clinical ... of AstraZeneca,s investigational anti-PD-L1 immune checkpoint inhibitor, MEDI4736, in ... 2 antiangiogenic cancer medicine. The planned study will assess ... solid tumors. The Phase I study is ...
Breaking Medicine Technology:Covalon Announces Strong Second Quarter Results 2Covalon Announces Strong Second Quarter Results 3DelMar Pharmaceuticals Presents Additional Data on the Potential of VAL-083 in the Treatment of Temozolomide-Resistant Glioblastoma Multiforme 2DelMar Pharmaceuticals Presents Additional Data on the Potential of VAL-083 in the Treatment of Temozolomide-Resistant Glioblastoma Multiforme 3DelMar Pharmaceuticals Presents Additional Data on the Potential of VAL-083 in the Treatment of Temozolomide-Resistant Glioblastoma Multiforme 4DelMar Pharmaceuticals Presents Additional Data on the Potential of VAL-083 in the Treatment of Temozolomide-Resistant Glioblastoma Multiforme 5Lilly and AstraZeneca to Collaborate on Immuno-Oncology Combination Clinical Trial in Solid Tumors 2Lilly and AstraZeneca to Collaborate on Immuno-Oncology Combination Clinical Trial in Solid Tumors 3Lilly and AstraZeneca to Collaborate on Immuno-Oncology Combination Clinical Trial in Solid Tumors 4Lilly and AstraZeneca to Collaborate on Immuno-Oncology Combination Clinical Trial in Solid Tumors 5Lilly and AstraZeneca to Collaborate on Immuno-Oncology Combination Clinical Trial in Solid Tumors 6Lilly and AstraZeneca to Collaborate on Immuno-Oncology Combination Clinical Trial in Solid Tumors 7Lilly and AstraZeneca to Collaborate on Immuno-Oncology Combination Clinical Trial in Solid Tumors 8Lilly and AstraZeneca to Collaborate on Immuno-Oncology Combination Clinical Trial in Solid Tumors 9Lilly and AstraZeneca to Collaborate on Immuno-Oncology Combination Clinical Trial in Solid Tumors 10Lilly and AstraZeneca to Collaborate on Immuno-Oncology Combination Clinical Trial in Solid Tumors 11Lilly and AstraZeneca to Collaborate on Immuno-Oncology Combination Clinical Trial in Solid Tumors 12Lilly and AstraZeneca to Collaborate on Immuno-Oncology Combination Clinical Trial in Solid Tumors 13Lilly and AstraZeneca to Collaborate on Immuno-Oncology Combination Clinical Trial in Solid Tumors 14
... oximeters available, Datex-Ohmeda s TuffSat is the ... transport, and EMS. TuffSat comes fully loaded ... index measurement) a quick, easy-to-use clinical ... perfusion at the sensor site. Now you ...
... clinical information. , ,S/5 Clinical Communications ... solutions that help you and your care ... You will have access to essential patient ... with your care team and specialists, independent ...
... safe and easy patient monitoring during MRI, ... special needs of the MRI environment. It allows ... MRI, promoting safety and flexibility., ,Though designed ... all the key benefits of the S/5 Monitoring ...
... and comprehensive solution for advanced arrhythmia ... (ARRWS) provides one compact, PC-based solution ... patients. It connects to Datex-Ohmeda Network ... up to 16 beds., ,The ...
Medicine Products: